My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 430

    1.

    Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes.

    Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A.

    Diabetes Care. 2004 Oct;27(10):2450-7.PMID: 15451915 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome.

    Bahia L, Aguiar LG, Villela N, Bottino D, Godoy-Matos AF, Geloneze B, Tambascia M, Bouskela E.

    Clinics (Sao Paulo). 2006 Oct;61(5):433-40.PMID: 17072441 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia.

    Otto C, Otto B, Frost RJ, Vogeser M, Pfeiffer AF, Spranger J, Parhofer KG.

    Acta Diabetol. 2007 Jun;44(2):65-8. Epub 2007 May 27.PMID: 17530469 [PubMed - indexed for MEDLINE]Related articles

    4.

    Therapeutic association of atorvastatin and insulin in cardiac ischemia: study in a model of type 2 diabetes with hyperlipidemia.

    Matafome P, Monteiro P, Nunes E, Louro T, Amaral C, Moedas AR, Gonçalves L, Providência L, Seiça R.

    Pharmacol Res. 2008 Sep-Oct;58(3-4):208-14. Epub 2008 Jul 23.PMID: 18692137 [PubMed - indexed for MEDLINE]Related articles

    5.

    Increased serum resistin levels in patients with type 2 diabetes are not linked with markers of insulin resistance and adiposity.

    Hasegawa G, Ohta M, Ichida Y, Obayashi H, Shigeta M, Yamasaki M, Fukui M, Yoshikawa T, Nakamura N.

    Acta Diabetol. 2005 Jun;42(2):104-9.PMID: 15944845 [PubMed - indexed for MEDLINE]Related articles

    6.

    Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes.

    Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB.

    J Clin Endocrinol Metab. 2005 Aug;90(8):4542-8. Epub 2005 May 24.PMID: 15914524 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.

    Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, Lai WT.

    Am J Cardiol. 2006 Mar 1;97(5):646-50. Epub 2006 Jan 9.PMID: 16490430 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia.

    Qu HY, Xiao YW, Jiang GH, Wang ZY, Zhang Y, Zhang M.

    Pharm Res. 2009 Apr;26(4):958-64. Epub 2008 Dec 10.PMID: 19082693 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.

    Bayés B, Granada ML, Lauzurica R, Pastor MC, Navarro M, Bonet J, Llopis MA, Romero R.

    Transplant Proc. 2005 Nov;37(9):3808-12.PMID: 16386546 [PubMed - indexed for MEDLINE]Related articles

    10.

    Associations of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-aged and older Chinese.

    Qi Q, Wang J, Li H, Yu Z, Ye X, Hu FB, Franco OH, Pan A, Liu Y, Lin X.

    Eur J Endocrinol. 2008 Nov;159(5):585-93. Epub 2008 Aug 27.PMID: 18753313 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Adiponectin and resistin serum levels in women with polycystic ovary syndrome during oral glucose tolerance test: a significant reciprocal correlation between adiponectin and resistin independent of insulin resistance indices.

    Lewandowski KC, Szosland K, O'Callaghan C, Tan BK, Randeva HS, Lewinski A.

    Mol Genet Metab. 2005 May;85(1):61-9. Epub 2005 Feb 12.PMID: 15862282 [PubMed - indexed for MEDLINE]Related articles

    12.

    Inflammation, insulin resistance, and adiposity: a study of first-degree relatives of type 2 diabetic subjects.

    Kriketos AD, Greenfield JR, Peake PW, Furler SM, Denyer GS, Charlesworth JA, Campbell LV.

    Diabetes Care. 2004 Aug;27(8):2033-40.PMID: 15277436 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance.

    Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ.

    Eur J Endocrinol. 2003 Oct;149(4):331-5.PMID: 14514348 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects.

    Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS.

    J Clin Endocrinol Metab. 2003 Oct;88(10):4848-56.PMID: 14557464 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus.

    Mojiminiyi OA, Abdella NA.

    Scand J Clin Lab Invest. 2007;67(2):215-25.PMID: 17366001 [PubMed - indexed for MEDLINE]Related articles

    16.

    Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian.

    Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS.

    Diabetes Care. 2003 Jun;26(6):1745-51.PMID: 12766104 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women.

    Kopp HP, Krzyzanowska K, Möhlig M, Spranger J, Pfeiffer AF, Schernthaner G.

    Int J Obes (Lond). 2005 Jul;29(7):766-71.PMID: 15917853 [PubMed - indexed for MEDLINE]Related articles

    18.

    Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes.

    van Hoek M, van Tol A, van Vark-van der Zee LC, Jansen H, Kastelein JJ, Sijbrands EJ, Dallinga-Thie GM.

    Curr Med Res Opin. 2009 Jan;25(1):93-101.PMID: 19210142 [PubMed - indexed for MEDLINE]Related articles

    19.

    Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes.

    von Eynatten M, Schneider JG, Hadziselimovic S, Hamann A, Bierhaus A, Nawroth PP, Dugi KA.

    Diabetes Care. 2005 Mar;28(3):754-5. No abstract available. PMID: 15735224 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo.

    Schneider JG, von Eynatten M, Schiekofer S, Nawroth PP, Dugi KA.

    Diabetes Care. 2005 Sep;28(9):2181-6.PMID: 16123487 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity